Page last updated: 2024-09-04

torcetrapib and ezetimibe

torcetrapib has been researched along with ezetimibe in 6 studies

Compound Research Comparison

Studies
(torcetrapib)
Trials
(torcetrapib)
Recent Studies (post-2010)
(torcetrapib)
Studies
(ezetimibe)
Trials
(ezetimibe)
Recent Studies (post-2010) (ezetimibe)
27328832,4845631,465

Protein Interaction Comparison

ProteinTaxonomytorcetrapib (IC50)ezetimibe (IC50)
NPC1-like intracellular cholesterol transporter 1Homo sapiens (human)0.37

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ansell, BJ1
Lumley, T; Psaty, BM1
Suckling, K1
Rosenson, RS1
Rizzoni, D; Rossi, GP1
Blum, D; Chaput, E; Derks, M; Kallend, D; Niesor, EJ; Staempfli, A1

Reviews

1 review(s) available for torcetrapib and ezetimibe

ArticleYear
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
    Current atherosclerosis reports, 2005, Volume: 7, Issue:1

    Topics: Anion Exchange Resins; Antihypertensive Agents; Azetidines; Benzenesulfonates; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Niacin; Quinolines

2005

Trials

1 trial(s) available for torcetrapib and ezetimibe

ArticleYear
Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
    Atherosclerosis, 2011, Volume: 219, Issue:2

    Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Biomarkers; Cholestanol; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Cross-Over Studies; Desmosterol; Esters; Ezetimibe; Homeostasis; Humans; Intestinal Absorption; Lipid Metabolism; Male; Mesocricetus; Models, Animal; Phytosterols; Quinolines; Sitosterols; Sulfhydryl Compounds; Switzerland

2011

Other Studies

4 other study(ies) available for torcetrapib and ezetimibe

ArticleYear
Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.
    JAMA, 2008, Mar-26, Volume: 299, Issue:12

    Topics: Azetidines; Biomarkers; Clinical Trials as Topic; Drug Approval; Ezetimibe; Humans; Hypolipidemic Agents; Quinolines; Risk; United States; United States Food and Drug Administration

2008
The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe.
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:7

    Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Design; Dyslipidemias; Ezetimibe; Humans; Quinolines

2008
Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:1

    Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Ezetimibe; Glucose; Humans; Insulin; Lipase; Lipoproteins, HDL; Niacin; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds

2010
Therapy: raising HDL cholesterol levels: a flight of Icarus?
    Nature reviews. Endocrinology, 2010, Volume: 6, Issue:5

    Topics: Atherosclerosis; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Niacin; Quinolines

2010